Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SciBase changes Certified Adviser to Carnegie Investment Bank AB (publ).

STOCKHOLM, SWEDEN, 21 August 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin, hereby announces change of Certified Adviser from Vator Securities to Carnegie Investment Bank AB (publ).SciBase has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will assume the role of Certified Adviser effective from September 1, 2024. Until then, Vator Securities will continue to act as the Certified Adviser for the company.

PRH has deregistered companies that have not filed their financial statements for registration

The Finnish Patent and Registration Office (PRH) has removed from the Finnish Trade Register about 3,600 limited liability companies and co-operatives that have not filed their financial statements for registration.Deregistration means that the business is out of action. The deregistered companies had not filed their financial statements despite reminder letters. The PRH had also informed the companies of the procedure using a number of communication channels. See the list of the companies deregistered on 19 August 2024 on the prh.fi website: · Read more about the deregistered

Specialty power rental company in New Zealand to become part of Atlas Copco Group

Nacka, Sweden, August 21, 2024: Generator Rental Services Limited (“GRS”), a company that provides specialty power rental solutions, will become part of Atlas Copco Group.GRS, which is headquartered in Auckland, was founded in 1997. The company has 58 employees and revenues of 23 MEUR (263 MSEK*) during the last fiscal year. The company provides specialty power and temperature control equipment, and the main customer groups can be found within power utility, general industry, and civil construction. “The specialty power rental market is a highly technical and regulated market driven by

Rejlers wins contract from the Swedish Transport Administration to future-proof Vänersborg Central Station

Rejlers has been commissioned by the Swedish Transport Administration to future-proof Vänersborg Central Station through an extensive capacity and function improvement project. The project aims to enable simultaneous operation of three trains and new platforms.The project includes a total reconstruction of the track system and new platforms to increase the station's capacity and create a safer environment for passengers. The work will also help to ensure that new safety requirements are met and make Vänersborg Central Station ready for the future. Rejlers is responsible for design,

Second Quarter Report Q2-2024

The Company has advanced well with its planned activities · First patient dosed in Paediatric Safety Study 0202 · Superior simulated pain efficacy in children with CT001 · New member of the Board of Directors, Anders Dyhr D-Toft · US launch finalization and final approvals still ongoing...Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2024. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.  Second quarter financial results

Correction: Multiconsult first quarter and first half result 2024 – very strong performance

Multiconsult (OSE: MULTI) Reference is made to the release issued 21 August 2024, 07:00 CET related to second quarter and first half result 2024: Heading referred to the first quarter 2024, the correct quarter should be second quarter 2024. Corrected release follows:  ______Multiconsult second quarter and first half result 2024 – very strong performance Multiconsult ASA (OSE: MULTI)Multiconsult delivered a very strong quarter, continuing the positive development with high activity and strong operational efficiency. The EBITA came in at NOK 185.7 million (55.6), equal to an EBITA

Composition of Kamux’s Shareholders’ Nomination Board

Kamux Corporation, Stock Exchange Release, 21.8.2024 at 9:15 Composition of Kamux’s Shareholders’ Nomination Board The shareholders of Kamux Corporation have nominated their representatives for the Shareholders’ Nomination Board for the term 2024–2025. The Shareholders’ Nomination Board consists of four members. The right to nominate the three members representing the shareholders is determined based on ownership in order of magnitude on the first business day of August preceding the Annual General Meeting, according to the shareholders’ register held by Euroclear Finland Ltd. In

Q2 Report – 30 June 2024

Flexion continues to grow. Revenue is up 14% and Gross Profit jumps 51% in the second quarter.April-June 2024 performance · Total revenue increased by 14% to GBP 17.7m (15.5)* · Total gross profit increased by 51% to GBP 3.6m (2.4) · Adjusted EBITDA[‡] increased by 1236% to GBP 1.1m (0.1) · Operating loss increased to GBP 0.8m (profit 0.03m) · EPS amounted to GBP -2.22 pence (-1.17 pence) · Operating cash flow amounted to GBP 0.6m (0.9) · Cash and cash equivalents increased to GBP 13.9m (12.7) January-June 2024 performance · Total revenue increased by 13% to

Interim Report Second Quarter 2024

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2024 – 30.06.2024. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:”Stenocare sales are lower than expected even though we have successfully managed to further improve financial health of the Company and launch new products in several markets, thereby delivering on our

Peab wins paving contract between Nordland and Troms in Northern Norway

Peab, through its subsidiary Peab Asfalt, has been commissioned to do the paving in  the extension of 82 kilometers of road in the so-called PPP project Hålogalandsvegen, which stretches between Nordland and Troms in Northern Norway. The customer is Skanska and the contract is worth NOK 256 million.PPP Hålogalandsvegen between Nordland and Troms is a project that Skanska has been commissioned to carry out by the Norwegian Public Roads Administration. It is a large-scale development of 82 kilometers of road to improve passability and safety, and reduce travel time in the Hålogaland region.

Terrafame applied for a strategic project status for the exploitation of the Kolmisoppi ore deposit under the EU’s Critical Raw Materials Act

Terrafame has submitted an application to the European Commission seeking a strategic project status for the Kolmisoppi project under the European Union’s Critical Raw Materials Act (CRMA). The CRMA came into effect in May 2024 and aims to sustainably ensure the availability of raw materials that are critical and strategic in terms of Europe’s economy and clean transition. The CRMA covers more than 30 raw materials, defining the battery grade nickel produced by Terrafame as well as cobalt and copper as strategic raw materials. Among other things, the status of a strategic project ensures

INIFY Laboratories: 62% revenue growth and strong international interest

STOCKHOLM - August 21, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, continues to deliver strong growth, with sales of SEK 3.6 million in the quarter – up 62% compared to the previous quarter. Total sales for the first half of the year amounted to SEK 5.8 million, with a cash balance at the end of the second quarter of SEK 46,1 million. “We have diagnosed more than 1,000 patients since the opening of our first laboratory and our market share in Sweden has grown to around 5%, which means that the continued growth potential in

Höegh LNG: Interim results for the quarter and first half ended 30 June 2024

Hamilton, Bermuda, 21 August 2024 - Höegh LNG Holdings Ltd. ("Höegh LNG") today reports its interim financial results for the quarter and first half ended 30 June 2024. The group reported an EBITDA of USD 75 million for the second quarter of 2024, compared to USD 79 million for the preceding quarter.In the second quarter, Hoegh Giant completed its commissioning for FSRU operations in Brazil. Furthermore, Höegh LNG and AIE announced an interim FSRU deployment of Hoegh Galleon with EGAS in Egypt for a period of about 20 months, after which the FSRU is expected to be deployed to AIE’s LNG

Hoist Finance has successfully issued bonds at a spread of 1,95%

PRESS RELEASEStockholm 21 August 2024   Hoist Finance AB (Hoist Finance) has successfully issued subsequent bonds to a nominal amount of SEK 200 million under its senior unsecured bond due 12 April 2027, bringing the total size of this bond to SEK 750 million. The bonds were issued at a price corresponding to a spread of STIBOR 3m+195 bps, marking yet another improvement to the terms of the original issue. "We are pleased to have completed this tap issue at such strong terms, showing great support from debt investors. Hoist Finance is on a journey to become the leading asset

Transaction in Own Shares

    21 August 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |20/08/2024|+------------------------------------------------------------

Interim report

January 1 – June 30, 2024The second quarter in figures · Net sales were TSEK 6,641 (5,085), +31%. · The loss after tax was TSEK 15,050 (11,352). · The loss per share was SEK 0.08 (0.16). · The cash flow from current operations was negative in the amount of TSEK 15,179 (13,054). · The gross margin was 69.1% (65.3%). · Electrode sales volume increased by 24% and was 14,106 (11,330) units. Repeat sales of electrodes to existing customers increased by 22%. January - June in figures · Net sales were TSEK 12,699 (10,234), +24%. · The loss after tax was TSEK 25,911 (

Cereno Scientific participating at ESC Congress 2024 to continue building presence in the global cardiovascular community

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, will participate at the ESC (European Society of Cardiology) Congress in London, August 30–September 2, 2024."We look forward to meeting with leaders within the global cardiovascular community at ESC to continue raising awareness about our portfolio of innovative drug candidates, learn about the most recent advances in the cardiovascular field and expand our network among academic and industry actors. With important milestones coming up, the

Implantica publishes Interim Report January – June 2024 (Q2)

RefluxStop™ is on a wave of success – carried by a multitude of published studies with excellent outcomes from leading European Reflux-centersSignificant events in the second quarter of 2024 · Module 1 review of Premarket Approval (PMA) application for RefluxStop™ completed by US FDA · Findings presented, all of which Implantica considers to be minor · Decided to submit response to Module 1 together with Module 2 submission · NHS Trust University Hospital Southampton started performing the RefluxStop™ procedure · NICE IPAC evaluation process assessing reimbursement of

Karnov Group reports second quarter results 2024

Delivering on the profitable growth strategyFinancial highlights second quarter · The Group’s net sales increased by 2.5% to SEK 623 m (608). Organic growth (constant currency) was 2.6%. Currency effect was 0.3%. · The Group’s adjusted EBITA amounted to SEK 132 m (109) with adjusted EBITA margin of 21.1% (18.0). · Net result amounted to SEK 1 m (-26). · Earnings per share before and after dilution amounted to SEK 0.01 (-0.24). · Adjusted free cash flow amounted to SEK 14 m (-15).      Comment from CEO Pontus Bodelsson Karnov Group delivers on its profitable growth

AAX Biotech appoints Patrik Strömberg to Board of Directors, enhancing leadership team

AAX Biotech is pleased to welcome Patrik Strömberg as new board member. Patrik Strömberg brings over two decades of extensive experience in the pharmaceutical industry, with a robust background in research and development, innovation management and business development.AAX Biotech is a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics. The company's two unique and patentable technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly

QUARTERLY REPORT: APRIL TO JUNE 2024

RECORD QUARTER: +74% YoY GROWTH IN SAAS API CALL VOLUMES AND TOTAL ARR OF 74 MSEKAPRIL TO JUNE 2024 · SaaS API Call Volumes 31.5 million (18.0), +74 % · SaaS ARR amounted to 43.7 MSEK (29.8), +47% · Total ARR amounted to 74.3 MSEK (58.2), +28% · Recurring revenues amounted to 19.1MSEK (14.6), +31% · Net Revenue Retention Rate (NRR) +134% (137) · Net sales amounted to 19.3 MSEK (14.8), +31% · Gross margin amounted to 79% (72) · EBITDA adjusted amounted to -6.3 MSEK (-13.9), +54% · Earnings per share amounted to -0.1 SEK (-0.2) JANUARY TO JUNE 2024 ·

MPCC: Invitation to Q2 2024 Earnings Call

MPC Container Ships ASA will publish its Q2 2024 financial report on Wednesday, August 28, 2024. Constantin Baack, CEO, and Moritz Fuhrmann, Co-CEO and CFO, will present the results in an earnings call at 15:00 CET / 09:00 ET on August 28, 2024, followed by a Q&A session. The earnings call can be accessed live via webcast and questions can be submitted in writing. A recording will be available on demand at the Company's website after the live event has concluded. The earnings call can be accessed through the following link: https://channel.royalcast.com/landingpage/hegnarmedia/

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Bergen, Norway, August 21, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update.   Highlights, including post period:   · BGBC016 1L NSCLC STK11m study continues to progress as planned. Enrollment in the Ph1b part completed. Data Safety Monitoring Board review of data from the final Ph1b dose cohort supports safety and tolerability of the combination of

There are no items matching the current filter
There are no more items matching the current filter
Back to top